247 results on '"Fenton, Terence"'
Search Results
2. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
3. Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth.
4. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
5. Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years
6. Safety and Immunogenicity of 2009 pH1N1 Vaccination in HIV-Infected Pregnant Women
7. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
8. Immunogenicity, Immunologic Memory, and Safety Following Measles Revaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy
9. Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1—Infected Children, Adolescents, and Young Adults
10. Immunogenicity and Immunologic Memory after Hepatitis B Virus Booster Vaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy
11. Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1-Infected Women
12. Longitudinal Analysis of Lymphocyte Ratios and HIV-1 Intracellular DNA Levels in Children
13. Effect of Maternal Immunization With 10-Valent Pneumococcus Conjugate Vaccine (PCV-10), 23-Valent Pneumococcus Polysaccharide Vaccine, or Placebo on the Immunogenicity of PCV-10 in Human Immunodeficiency Virus–Exposed Uninfected Infants: A Randomized Clinical Trial
14. Persistence of Human Immunodeficiency Virus (HIV) Type 1 DNA in Peripheral Blood despite Prolonged Suppression of Plasma HIV-1 RNA in Children
15. Recombinant CD4-IgG2 in Human Immunodeficiency Virus Type 1-Infected Children: Phase 1/2 Study
16. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
17. Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIV
18. Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial
19. High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)
20. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
21. Immunogenicity of Conjugated and Polysaccharide Pneumococcal Vaccines Administered During Pregnancy or Postpartum to Women With HIV.
22. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
23. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1–infected children
24. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
25. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers
26. Persistence of pediatric post traumatic stress disorder after 2 years
27. Psychiatric comorbidity in childhood post traumatic stress disorder
28. Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children
29. Prevalence of medical technology assistance among children in Massachusetts in 1987 and 1990
30. Maternal and child posttraumatic stress disorder in cases of child maltreatment
31. Schoolchildren with HIV infection: a survey of the nation's largest school districts
32. Child maltreatment and the development of posttraumatic stress disorder
33. Psychiatric diagnoses of maltreated children: preliminary findings
34. Parental substance abuse and the nature of child maltreatment
35. Stimulant medication and attention deficit-hyperactivity disorder: the child's perspective
36. Degree of Agreement in Plasma Fibrinogen Among Two Functional and One Immunonephelometric Assays
37. Early developmental history and pediatric posttraumatic stress disorder
38. Differences in neuropsychological and academic achievement between adolescent delinquents and status offenders
39. Medical and developmental histories of maltreated children
40. Posttraumatic stress disorder among children clinically diagnosed as borderline personality disorder
41. Child maltreatment histories among runaway and delinquent children
42. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
43. Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children
44. Long-Term Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents
45. Associations of Host Genetic Variants on CD4+ Lymphocyte Count and Plasma HIV-1 RNA in Antiretroviral Naïve Children
46. Clinical evaluation of juvenile delinquents: who gets court referred?
47. Genetic Variants in the Host Restriction Factor APOBEC3G are Associated With HIV-1–Related Disease Progression and Central Nervous System Impairment in Children
48. HLA Alleles are Associated With Altered Risk for Disease Progression and Central Nervous System Impairment of HIV-Infected Children
49. Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children
50. CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1–Infected Children Receiving Highly Active Antiretroviral Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.